CN112823036B - 用于治疗与sting活性有关的疾病的化合物和组合物 - Google Patents
用于治疗与sting活性有关的疾病的化合物和组合物 Download PDFInfo
- Publication number
- CN112823036B CN112823036B CN201980057319.9A CN201980057319A CN112823036B CN 112823036 B CN112823036 B CN 112823036B CN 201980057319 A CN201980057319 A CN 201980057319A CN 112823036 B CN112823036 B CN 112823036B
- Authority
- CN
- China
- Prior art keywords
- independently selected
- alkyl
- optionally substituted
- disease
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411419807.9A CN120004785A (zh) | 2018-07-03 | 2019-07-02 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693768P | 2018-07-03 | 2018-07-03 | |
| US62/693,768 | 2018-07-03 | ||
| US201962861825P | 2019-06-14 | 2019-06-14 | |
| US62/861,825 | 2019-06-14 | ||
| PCT/US2019/040317 WO2020010092A1 (en) | 2018-07-03 | 2019-07-02 | Compounds and compositions for treating conditions associated with sting activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411419807.9A Division CN120004785A (zh) | 2018-07-03 | 2019-07-02 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112823036A CN112823036A (zh) | 2021-05-18 |
| CN112823036B true CN112823036B (zh) | 2024-11-08 |
Family
ID=67441650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980057319.9A Active CN112823036B (zh) | 2018-07-03 | 2019-07-02 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| CN202411419807.9A Pending CN120004785A (zh) | 2018-07-03 | 2019-07-02 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411419807.9A Pending CN120004785A (zh) | 2018-07-03 | 2019-07-02 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11618749B2 (https=) |
| EP (1) | EP3817820A1 (https=) |
| JP (2) | JP7566731B2 (https=) |
| CN (2) | CN112823036B (https=) |
| MA (1) | MA53095A (https=) |
| TW (1) | TWI873098B (https=) |
| WO (1) | WO2020010092A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ－スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| CN112823036B (zh) * | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| TW202043198A (zh) * | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| MA54753A (fr) * | 2019-01-17 | 2021-11-24 | Ifm Due Inc | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
| US20230092163A1 (en) * | 2019-06-14 | 2023-03-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN114761804A (zh) | 2019-06-21 | 2022-07-15 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
| EP4085061A1 (en) * | 2019-12-31 | 2022-11-09 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2021161230A1 (en) * | 2020-02-12 | 2021-08-19 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
| JP6912016B1 (ja) * | 2020-04-10 | 2021-07-28 | 小野薬品工業株式会社 | Ｓｔｉｎｇ作動化合物 |
| EP4134134A4 (en) * | 2020-04-10 | 2023-12-27 | ONO Pharmaceutical Co., Ltd. | STING AGONISTIC COMPOUND |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| EP4247790B1 (en) * | 2020-11-23 | 2024-10-09 | Regor Pharmaceuticals, Inc. | Sting antagonists and uses thereof |
| WO2022140397A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| US20240060982A1 (en) | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
| EP4267129A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4267128A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4274826A1 (en) * | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Oxalamide compounds and compositions for treating conditions associated with sting activity |
| JP2024502470A (ja) * | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| TW202235073A (zh) | 2021-01-08 | 2022-09-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關的病狀之化合物及組合物 |
| US20240101556A1 (en) | 2021-01-08 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| AU2022325543A1 (en) * | 2021-08-11 | 2024-02-15 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
| CN115710255B (zh) * | 2021-08-23 | 2025-05-06 | 上海交通大学 | 一类含有苯并杂环取代的脲类衍生物及其制备和用途 |
| CN116789641A (zh) * | 2022-03-17 | 2023-09-22 | 中国科学院上海药物研究所 | 二氢异喹啉类化合物及其医药用途 |
| WO2024032597A1 (zh) * | 2022-08-11 | 2024-02-15 | 杭州中美华东制药有限公司 | 具有sting抑制作用的酰胺类化合物及其药物组合物和用途 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CA3267008A1 (en) * | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| TW202432114A (zh) * | 2022-10-26 | 2024-08-16 | 德商百靈佳殷格翰國際股份有限公司 | 可活化sting之雜環化合物 |
| TW202432545A (zh) * | 2022-10-26 | 2024-08-16 | 德商百靈佳殷格翰國際股份有限公司 | 可活化sting之雜環化合物 |
| CN120476113A (zh) * | 2022-12-20 | 2025-08-12 | 杭州中美华东制药有限公司 | 具有sting抑制作用的含肟化合物及其药物组合物和用途 |
| CN116023321B (zh) * | 2022-12-30 | 2024-11-29 | 中国药科大学 | Sting抑制剂前药及其医药用途 |
| CN120794957A (zh) * | 2024-05-14 | 2025-10-17 | 中国药科大学 | 苯并含氮杂环类sting抑制剂及其医药用途 |
| CN121342824A (zh) * | 2024-07-16 | 2026-01-16 | 中国药科大学 | 四氢萘啶类sting抑制剂及其医药用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| CN1678589A (zh) * | 2002-09-05 | 2005-10-05 | 安万特医药股份有限公司 | 作为药物的新氨基吲唑衍生物与含有它们的药物组合物 |
| WO2017034420A1 (en) * | 2015-08-27 | 2017-03-02 | Auckland Uniservices Limited | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy |
| CN114761804A (zh) * | 2019-06-21 | 2022-07-15 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120046290A1 (en) | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| WO2003028720A1 (en) | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| JP4751063B2 (ja) | 2002-05-17 | 2011-08-17 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物 |
| PL376789A1 (pl) | 2002-12-12 | 2006-01-09 | Aventis Pharma S.A. | Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy |
| WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| US20080255153A1 (en) * | 2007-03-28 | 2008-10-16 | Biovitrum Ab (Publ) | New compounds |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| WO2012075380A1 (en) | 2010-12-03 | 2012-06-07 | The Trustees Of The University Of Pennsylvania | Tip60 inhibitors |
| AU2012256237B2 (en) | 2011-05-13 | 2017-01-05 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| CN109394752A (zh) | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| WO2016049774A1 (en) | 2014-10-03 | 2016-04-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| JP2019510802A (ja) * | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| US11452717B2 (en) | 2017-01-10 | 2022-09-27 | Sanford Burnham Prebys Medical Discovery Institute | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof |
| JP2020524718A (ja) * | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| CN109180649B (zh) | 2017-08-18 | 2021-03-12 | 四川百利药业有限责任公司 | 一种含吲哚环的ido抑制剂及其制备方法 |
| WO2019122202A1 (en) | 2017-12-20 | 2019-06-27 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| EP3556362A1 (en) | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| US20210236466A1 (en) | 2018-07-03 | 2021-08-05 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN112823036B (zh) * | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| WO2020106741A1 (en) | 2018-11-19 | 2020-05-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP3883651A1 (en) | 2018-11-19 | 2021-09-29 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| MA54753A (fr) | 2019-01-17 | 2021-11-24 | Ifm Due Inc | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
| TW202043198A (zh) | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| WO2020191227A1 (en) | 2019-03-20 | 2020-09-24 | Cornell University | Methods for controlling prostaglandin-mediated biological processes |
| WO2020236586A1 (en) | 2019-05-17 | 2020-11-26 | Ifm Due, Inc. | N-hetaryl-squaramide compounds for treating conditions associated with sting activity |
| US20220227760A1 (en) | 2019-05-29 | 2022-07-21 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20230092163A1 (en) | 2019-06-14 | 2023-03-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2021067801A1 (en) | 2019-10-03 | 2021-04-08 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2021067805A1 (en) | 2019-10-03 | 2021-04-08 | Ifm Due, Inc. | Oxalamide heterobycyclic compounds and compositions for treating conditions associated with sting activity |
| WO2021067791A1 (en) | 2019-10-03 | 2021-04-08 | Ifm Due, Inc. | Oxalamide compounds and compositions for treating conditions associated with sting activity |
| EP4085061A1 (en) | 2019-12-31 | 2022-11-09 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| JP7756643B2 (ja) | 2019-12-31 | 2025-10-20 | ノバルティス ファーマ アーゲー | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| US20220024919A1 (en) | 2020-07-15 | 2022-01-27 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| PY2157405A (es) | 2020-07-15 | 2022-04-22 | Ifm Due Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting |
| WO2022015938A1 (en) | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4182310A1 (en) | 2020-07-15 | 2023-05-24 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20220024906A1 (en) | 2020-07-15 | 2022-01-27 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20230250106A1 (en) | 2020-07-15 | 2023-08-10 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4182030A1 (en) | 2020-07-15 | 2023-05-24 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
-
2019
- 2019-07-02 CN CN201980057319.9A patent/CN112823036B/zh active Active
- 2019-07-02 JP JP2021522931A patent/JP7566731B2/ja active Active
- 2019-07-02 TW TW108123334A patent/TWI873098B/zh active
- 2019-07-02 WO PCT/US2019/040317 patent/WO2020010092A1/en not_active Ceased
- 2019-07-02 US US16/460,381 patent/US11618749B2/en active Active
- 2019-07-02 EP EP19745408.5A patent/EP3817820A1/en active Pending
- 2019-07-02 CN CN202411419807.9A patent/CN120004785A/zh active Pending
- 2019-07-02 MA MA053095A patent/MA53095A/fr unknown
-
2023
- 2023-03-01 US US18/116,183 patent/US20240083895A1/en active Pending
-
2024
- 2024-06-11 JP JP2024094148A patent/JP2024116295A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| CN1678589A (zh) * | 2002-09-05 | 2005-10-05 | 安万特医药股份有限公司 | 作为药物的新氨基吲唑衍生物与含有它们的药物组合物 |
| WO2017034420A1 (en) * | 2015-08-27 | 2017-03-02 | Auckland Uniservices Limited | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy |
| CN114761804A (zh) * | 2019-06-21 | 2022-07-15 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
Non-Patent Citations (2)
| Title |
|---|
| Mosaad Sayed Mohamed et al..Design, Synthesis and Cancer Cell Line Activities of Pyrazolo[3,4-b]pyridine Derivatives.《Open Journal of Medicinal Chemistry》.2012,第2卷第78-88页. * |
| Targeting STING with covalent small-molecule inhibitors;Simone M. Haag et al.;《Nature》;第559卷;第269页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI873098B (zh) | 2025-02-21 |
| WO2020010092A1 (en) | 2020-01-09 |
| CN120004785A (zh) | 2025-05-16 |
| CN112823036A (zh) | 2021-05-18 |
| EP3817820A1 (en) | 2021-05-12 |
| US11618749B2 (en) | 2023-04-04 |
| JP2024116295A (ja) | 2024-08-27 |
| TW202014408A (zh) | 2020-04-16 |
| JP7566731B2 (ja) | 2024-10-15 |
| MA53095A (fr) | 2021-05-12 |
| JP2021529833A (ja) | 2021-11-04 |
| US20200172534A1 (en) | 2020-06-04 |
| US20240083895A1 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112823036B (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN112823151B (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN115348957B (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN113382772B (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| TW202043198A (zh) | 用於治療與sting活性相關之病況的化合物及組合物 | |
| CN115279770A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| WO2020106741A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| CN116157394A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| WO2021067791A1 (en) | Oxalamide compounds and compositions for treating conditions associated with sting activity | |
| WO2020243519A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| CN116528862A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN113874010A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN116261452A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN117561253A (zh) | 用于治疗与sting活性有关的病症的化合物和组合物 | |
| WO2022015938A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| US20220024919A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| WO2023137034A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| CN117321048A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
| CN116964045A (zh) | 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物 | |
| HK40048005A (en) | Compounds and compositions for treating conditions associated with sting activity | |
| HK40048003A (en) | Compounds and compositions for treating conditions associated with sting activity | |
| HK40048005B (zh) | 用於治疗与sting活性有关的疾病的化合物和组合物 | |
| HK40048003B (zh) | 用於治疗与sting活性有关的疾病的化合物和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40048005 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20250205 Address after: Basel, SUI Patentee after: NOVARTIS PHARMA AG Country or region after: Switzerland Address before: U.S.A. Patentee before: Afumdeyou Co.,Ltd. Country or region before: U.S.A. |
|
| TR01 | Transfer of patent right |